“…Based on the experience of the 22 patients with early treatment failure who were nonrandomly assigned to receive blinatumomab therapy, the success rate in the salvage setting was low. This outcome supports findings of previous studies that identified high bone marrow blast percentage as a risk factor for blinatumomab resistance…”

“…In the present study, most patients experienced grade ≥3 TEAEs, consistent with that previously reported in Japanese patients and in global studies, including the expanded access international study of pediatric patients (RIALTO) and the global study in adult patients (TOWER) [36‒41]. The most frequent grade ≥3 TEAEs and AEs of interest such as nausea, febrile neutropenia, neutropenia, pyrexia, and CRS reported in this study were consistent with the phase 1b/2 and phase 1b studies in the Japanese adult and pediatric patients, respectively, and the global studies (Table 5) [36‒41]. In the current study, grade ≥3 neurotoxicity and CRS were not observed in adult patients and were limited to 1 pediatric patient.…”

“…Owing to the improved efficacy in adult patients, a higher proportion of adult patients (79%) received HSCT compared with pediatric patients (12%). However, the response rates reported in the Japanese patients in this expansion cohort study were as expected and comparable to those previously reported in Japanese and Asian patients, as well as those reported in global studies (Table 5)[36][37][38][39][40][41]43].…”

“…The duration of OS multivariately increased with increasing exposure, supporting the clinical benefit of blinatumomab in prolonging the duration of OS. This is consistent with the findings from the phase 3 study, which reported an HR for OS of 0.71 (95% CI: 0.55–0.93; P = .01) for blinatumomab treatment vs SOC treatment…”